跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
二甲双胍恩格列净片(Ⅵ) - NMPA Drug Approval Details
Approvals
/
NMPA
/
Metformin Hydrochloride and Empagliflozin Tablets(Ⅵ)
Approved
化学药品
Metformin Hydrochloride and Empagliflozin Tablets(Ⅵ)
Boehringer Ingelheim International GmbH
🇨🇳 National Medical Products Administration
Approval Date
Dec 20, 2023
Approval ID
8WHZRSuO2Ri
Company
Boehringer Ingelheim International GmbH
Type
化学药品
Approval Details
Approval Id
8WHZRSuO2Ri
Approval Number
国药准字HJ20190028
Generic Name
二甲双胍恩格列净片(Ⅵ)
Generic Name En
Metformin Hydrochloride and Empagliflozin Tablets(Ⅵ)
Drug Type
化学药品
Dosage Form
片剂
Strength
每片含盐酸二甲双胍1000mg与恩格列净12.5mg
Reg Date
2023-12-20
Expired Date
2028-12-19
Company Name
Boehringer Ingelheim International GmbH
Company Address
Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
Production Company Name
Boehringer Ingelheim Pharma GmbH & Co. KG
Production Company Address
Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
Company Detail Path
/organization/boehringer-ingelheim-international-gmbh
Production Company Detail Path
/organization/boehringer-ingelheim-pharma-gmbh-and-co-kg
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 20, 2023
Approval ID
8WHZRSuO2Ri
Type
化学药品
Back to NMPA Approvals